1013 ET - Centene's early share-price drop signals that reassuring words during its earnings call failed to soothe investors' worries about medical costs. The company stuck to its 2025 guidance but bumped up a measure of medical costs, and it flagged spending on high-cost drugs. Wall Street is concerned about the company's Medicaid business as well as the Affordable Care Act marketplace plans. Shares fall 7.3% to $57.10.(anna.mathews@wsj.com)
(END) Dow Jones Newswires
April 25, 2025 10:13 ET (14:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。